Evidence map›Paper›PMID 41815585›Full record

ArticleCureus2026

Challenges and Opportunities in Evaluating Novel Drug-Radiotherapy Combinations.

Shelby Lane, Charles B Simone, Jessica Schuster, Jason Efstathiou, Steven Eric Finkelstein, Vatsal Patel, Yun Li, Susannah G Ellsworth, Mitchell Oscar Finkelstein, Thomas Kim and 2 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shelby LaneRadiation Oncology, Baptist Memorial Hospital, Memphis, USA.
Charles B SimoneRadiation Oncology, New York Proton Center, New York, USA.
Jessica SchusterRadiation Oncology, University of Wisconsin, Madison, USA.
Jason EfstathiouRadiation Oncology, Massachusetts General Hospital, Boston, USA.
Steven Eric FinkelsteinAssociated Medical Professionals of New York, US Urology Partners, Syracuse, USA.
Vatsal PatelRadiation Oncology, I Am Still Alive, LLC, Phoenix, USA.
Yun LiRadiation Oncology, City of Hope Comprehensive Cancer Center, Duarte, USA.
Susannah G EllsworthRadiation Oncology, University of Pittsburgh Medical Center, Pittsburgh, USA.
Mitchell Oscar FinkelsteinBarrett, The Honors College, Arizona State University, Tempe, USA.
Thomas KimRadiation Oncology, Rush University Medical Center, Chicago, USA.
Lawrence R KleinbergRadiation Oncology, Johns Hopkins University School of Medicine, Baltimore, USA.
Michael TomblynRadiation Oncology, Baptist Memorial Hospital, Memphis, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Given the recent explosion in the number and diversity of novel targeted systemic therapies, many future advances in cancer treatment may result from improving the therapeutic ratio of radiotherapy (RT) by exploiting combinations of RT and novel targeted systemic therapies. Despite the abundance of preclinical models suggesting that new agents can improve the efficacy of RT, early-phase clinical trials have not demonstrated expected synergies or even additive efficacy between RT and these agents, particularly in trials of concurrent immunotherapy/RT. This underscores the ongoing need to develop well-formulated and well-executed early-phase clinical trials in this space that are based on sound science and are well-positioned to discern the optimal ways to combine these treatment modalities. What are the barriers to the completion of early-phase clinical trials combining RT and drugs?

Indexed as

clinical trialsimmunotherapyoncologyradiotherapyresearch

Identifiers

PMID41815585
PMCPMC12974542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.